Adaptimmune Therapeutics Plc ADR [ADAP] stock prices are down -2.60% to $0.18 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADAP shares have gain 34.70% over the last week, with a monthly amount glided 221.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 29, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Mizuho downgraded its rating to Neutral on June 26, 2025, and kept the price target unchanged to $0.50. On July 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $4 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $3.15 on May 30, 2024. Bryan Garnier initiated its recommendation with a Buy and recommended $3.60 as its price target on March 24, 2023. Guggenheim upgraded its rating to Buy for this stock on January 03, 2023, but kept the price target unchanged to $5. In a note dated November 09, 2022, Mizuho upgraded an Buy rating on this stock but restated the target price of $9.
The stock price of Adaptimmune Therapeutics Plc ADR [ADAP] has been fluctuating between $0.04 and $0.91 over the past year. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.18 at the most recent close of the market. An investor can expect a potential return of 1472.22% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
The Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] reported sales of 65.66M for trailing twelve months, representing a drop of -89.22%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.52%, Pretax Profit Margin comes in at -2.52%, and Net Profit Margin reading is -2.61%. To continue investigating profitability, this company’s Return on Assets is posted at -1.3, Equity is 41.03 and Total Capital is -2.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP]’s Current Ratio is 1.52. Further, the Quick Ratio stands at 1.29, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 0.73.
Transactions by insiders
Recent insider trading involved Wood Gavin, Chief Financial Officer, that happened on Sep 02 ’25 when 96000.0 shares were sold. Chief Financial Officer, Gavin Wood completed a deal on Sep 02 ’25 to buy 16000.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 0.21 million shares on Aug 28 ’25.
